



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 25/28 (2006.01)
C07K 16/18 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2022/052763

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,524 26 March 2021 (26.03.2021) US
63/269,225 11 March 2022 (11.03.2022) US

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US).

(72) Inventors: **NANJUNDA, Rupesh**; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). **CHOWDHURY, Partha**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **SHA, Fern**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US).

(74) Agent: **SHIRTZ, Joseph F.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUMANIZED ANTIBODIES AGAINST PAIRED HELICAL FILAMENT TAU AND USES THEREOF




FIG. 1

(57) Abstract: Humanized anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, conjugates and fusion constructs of the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*